PT100524A - Emulsoes aquosas de oleos de origem vegetal e/ou marinha contendo fosfolipidos e composicoes que as contem - Google Patents

Emulsoes aquosas de oleos de origem vegetal e/ou marinha contendo fosfolipidos e composicoes que as contem

Info

Publication number
PT100524A
PT100524A PT100524A PT10052492A PT100524A PT 100524 A PT100524 A PT 100524A PT 100524 A PT100524 A PT 100524A PT 10052492 A PT10052492 A PT 10052492A PT 100524 A PT100524 A PT 100524A
Authority
PT
Portugal
Prior art keywords
pct
phospholipids
dha
epa
fatty acids
Prior art date
Application number
PT100524A
Other languages
English (en)
Other versions
PT100524B (pt
Inventor
Carin Larsson-Backstrom
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of PT100524A publication Critical patent/PT100524A/pt
Publication of PT100524B publication Critical patent/PT100524B/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
    • A23D7/01—Other fatty acid esters, e.g. phosphatides
    • A23D7/011—Compositions other than spreads
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J7/00—Phosphatide compositions for foodstuffs, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT100524A 1991-05-30 1992-05-27 Emulsoes aquosas de oleos de origem vegetal e/ou marinha contendo fosfolipidos e composicoes que as contem PT100524B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9101642A SE9101642D0 (sv) 1991-05-30 1991-05-30 Phospholipids

Publications (2)

Publication Number Publication Date
PT100524A true PT100524A (pt) 1993-08-31
PT100524B PT100524B (pt) 1999-08-31

Family

ID=20382886

Family Applications (1)

Application Number Title Priority Date Filing Date
PT100524A PT100524B (pt) 1991-05-30 1992-05-27 Emulsoes aquosas de oleos de origem vegetal e/ou marinha contendo fosfolipidos e composicoes que as contem

Country Status (14)

Country Link
US (1) US5434183A (pt)
EP (1) EP0660708B1 (pt)
JP (1) JP3387498B2 (pt)
AT (1) ATE216227T1 (pt)
AU (1) AU657969B2 (pt)
CA (1) CA2109611A1 (pt)
DE (1) DE69232564T2 (pt)
ES (1) ES2174833T3 (pt)
IE (1) IE921477A1 (pt)
NZ (1) NZ242697A (pt)
PT (1) PT100524B (pt)
SE (1) SE9101642D0 (pt)
SG (1) SG64864A1 (pt)
WO (1) WO1992021335A1 (pt)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4133694C2 (de) * 1991-10-11 1993-10-07 Fresenius Ag Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen
WO1994022313A1 (en) * 1993-04-01 1994-10-13 Ici Australia Operations Proprietary Limited Pan release agent
WO1994028732A1 (en) * 1993-06-07 1994-12-22 Ici Australia Operations Proprietary Limited Reduction of moisture loss from plant and animal matter
US5716614A (en) * 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
WO1996010922A1 (de) * 1994-10-05 1996-04-18 Milupa Aktiengesellschaft Phospholipidhaltige fettmischung mit lcp-fettsäuren
JPH0987176A (ja) * 1995-09-26 1997-03-31 Shiseido Co Ltd 糸球体腎炎抑制剤
KR100293297B1 (ko) * 1995-11-24 2001-08-07 씨.지. 온닝크 어유기재조성물
IT1277953B1 (it) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
DE19608137A1 (de) * 1996-03-02 1997-09-04 Meyer Lucas Gmbh & Co Lipid-Zubereitungen für diätetische Zwecke
DE19644518A1 (de) * 1996-10-25 1998-04-30 Nutricia Nv Wässrige Fettemulsion, diese enthaltende Nahrung und deren Verwendung
US6344482B1 (en) 1997-04-23 2002-02-05 Andrew L. Stoll Omega-3 fatty acids in the treatment of bipolar disorder
US6852870B2 (en) * 1999-03-22 2005-02-08 Andrew Stoll Omega-3 fatty acids in the treatment of depression
US7906153B2 (en) * 1998-04-08 2011-03-15 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating multiple sclerosis
US5955102A (en) 1998-09-04 1999-09-21 Amway Corporation Softgel capsule containing DHA and antioxidants
CO5150202A1 (es) 1998-12-31 2002-04-29 Kimberly Clark Co Composicion de tisu facial y metodo para usarla para el secuestro de irritantes de la piel de la secrecion nasal
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US8753675B1 (en) * 2000-01-20 2014-06-17 Raj K. Chopra Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications
CA2304906A1 (en) * 2000-04-07 2001-10-07 1411198 Ontario Limited 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
GB0014437D0 (en) * 2000-06-14 2000-08-09 Porter William L Immune response stimulation
DE60123603T2 (de) * 2000-06-14 2007-08-16 William Leslie Diss Porter Lipide zur änderung des abwehrsystems
US20020155161A1 (en) * 2000-12-29 2002-10-24 Deckelbaum Richard J. Use of IV emulsions with different triglyceride composition, particle size and apolipoprotein E for targeted tissue delivery of hydrophobic compounds
MX281182B (es) * 2001-05-14 2010-11-22 Martek Biosciences Boulder Corp Produccion y uso de una fraccion rica en lipidos polares, que contienen acidos grasos altamente insaturados omega-3 y/u omega-6, procedentes de microbios, de semillas de plantas y de organismos marinos geneticamente modificados.
EP1279400A1 (en) * 2001-07-25 2003-01-29 Target Hit sa Modifying the fatty acid composition of cell membranes of organs and tissues
ATE363486T1 (de) 2001-07-27 2007-06-15 Neptune Technologies & Bioress Flavonoide und mehrfach ungesättigte fettsäuren enthaltende natürliche phospholipide maritimen ursprungs sowie deren anwendungen
AU2002319961A1 (en) * 2001-07-27 2003-02-17 N.V. Nutricia Enteral compositions for the prevention and/or treatment of sepsis
AU2002323409A1 (en) * 2001-08-24 2003-03-10 Martek Biosciences Boulder Corporation Products containing highly unsaturated fatty acids for use by women and their children during stages of preconception, pregnancy and lactation/post-partum
EP1489915A4 (en) * 2002-03-08 2005-09-14 Monsanto Technology Llc TREATMENT AND PREVENTION OF INFLAMMATORY DISORDERS
EP1569525A1 (en) * 2002-11-26 2005-09-07 Phares Pharmaceutical Research N.V. Marine lipid compositions
ITMI20030036A1 (it) * 2003-01-13 2004-07-14 Hunza Di Pistolesi Elvira & C S A S Preparazioni farmacologiche o dietetiche costituite da
US8633247B2 (en) 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Method for decreasing cartilage damage in dogs
US8633246B2 (en) 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Omega-3 fatty acids for osteoarthritis
ES2229935B1 (es) * 2003-10-10 2006-10-01 Universitat De Les Illes Balears Utilizacion del acido hidroxioleico y compuestos analagos del mismo como aditivos alimentarios funcionales.
US7935365B2 (en) 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
US8052992B2 (en) 2003-10-22 2011-11-08 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
US20050130937A1 (en) 2003-10-22 2005-06-16 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
AU2004289353B2 (en) * 2003-11-12 2011-02-10 Children's Medical Center Corporation Treatment and prevention of liver disease associated with parenteral nutrition (PN)
US8075910B2 (en) * 2004-05-20 2011-12-13 Pbm Pharmaceuticals, Inc. Oral compositions comprising edible oils and vitamins and/or minerals and methods for making oral compositions
ES2296206T3 (es) * 2004-06-10 2008-04-16 Kellogg Company Aplicacion topica de aceites marinos a alimentos.
MXPA06015203A (es) * 2004-07-01 2007-03-27 Nestec Sa Formulacion de dieta para osteoartritis canina.
AU2005302852B2 (en) * 2004-11-12 2011-06-02 N.V. Nutricia Food composition comprising a protein-and a lipid fraction for rapidly attenuating inflammatory responses
FR2880538B1 (fr) * 2005-01-07 2008-12-26 Polaris Soc Par Actions Simpli Composition cosmetique et cosmeceutique a base d'huiles de poissons, de phospholipides d'origine marine avec ou sans huile de pepins de franboise
GB0506788D0 (en) * 2005-04-04 2005-05-11 Biosea Man As Process
WO2007058523A1 (en) * 2005-11-17 2007-05-24 N.V. Nutricia Composition with docosapentaenoic acid
ES2277557B1 (es) 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
AU2006327064B2 (en) * 2005-12-21 2012-04-26 Brudy Technology, S.L. Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage
US20070225370A1 (en) * 2006-03-21 2007-09-27 Joar Opheim Nutritional Compositions and Methods
US20080044487A1 (en) 2006-05-05 2008-02-21 Natural Asa Anti-inflammatory properties of marine lipid compositions
WO2008149177A2 (en) * 2006-05-05 2008-12-11 Natural Asa Marine lipid compositions and uses thereof
WO2008143642A2 (en) * 2006-11-09 2008-11-27 Children's Medical Center Corporation Methods of treating and preventing ocular neovascularization with omega-3 polyunsaturated fatty acids
WO2008070467A2 (en) * 2006-12-01 2008-06-12 Joseph Thomas Weishaar Method for preventing chronic disease
KR101394594B1 (ko) * 2007-02-15 2014-05-14 슈 생-쥐스땡 골 재흡수 및 골 형성 간의 불균형을 보정하는 방법 및 이를 위한 키트 및 조성물
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
EP2612672A1 (en) 2007-03-28 2013-07-10 Aker BioMarine AS Bioeffective krill oil compositions
CN101680887B (zh) * 2007-03-30 2014-06-25 褚圣-贾斯汀公司 测定脊柱侧凸风险的方法
WO2008140026A1 (ja) * 2007-05-11 2008-11-20 Bizen Chemical Co., Ltd. 新規のロイコトリエン受容体アンタゴニスト
EP2732709A1 (en) * 2007-08-29 2014-05-21 Aker BioMarine AS A new method for making krill meal
US20100226977A1 (en) * 2007-08-29 2010-09-09 Aker Biomarine Asa Low viscosity phospholipid compositions
US20090099261A1 (en) * 2007-09-25 2009-04-16 Isi Brands Inc. Omega-3 mixtures
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
GB0808479D0 (en) * 2008-05-09 2008-06-18 Uni I Oslo Topical compositions
EP4137128A1 (en) 2008-09-02 2023-02-22 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and a statin, and methods of using same
NZ594395A (en) 2009-02-10 2014-01-31 Amarin Pharmaceuticals Ie Ltd Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
US8372812B2 (en) * 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
NZ720946A (en) 2009-04-29 2017-09-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MX2011011538A (es) 2009-04-29 2012-06-13 Amarin Pharma Inc Composicion farmaceutica estable y metodos de uso de la misma.
SI3318255T1 (sl) 2009-06-15 2021-07-30 Amarin Pharmaceuticals Ireland Limited Kompozicije in metode za zdravljenje kapi pri subjektu, ki prejema sočasno zdravljenje s statinom
NO333013B1 (no) * 2009-07-06 2013-02-18 Smartfish As Sammensetning omfattende bioaktive aminosyrer eller derivater derav og marin olje i en stabil olje-i-vannemulsjon, og fremgangsmate for fremstilling av nevnte sammensetning.
CA2775339C (en) 2009-09-23 2017-03-28 Amarin Corporation Plc Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
PT2493478T (pt) 2009-10-29 2018-04-03 Acasti Pharma Inc Composições terapêuticas concentradas de fosfolípidos
WO2011091160A1 (en) * 2010-01-20 2011-07-28 Henry Wu Custom-formulated phospholipid microbubbles and methods and uses thereof
US20110206741A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation DHA Triglyceride Emulsions
WO2011103512A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha free fatty acid emulsions
US20110200644A1 (en) * 2010-02-18 2011-08-18 Martek Biosciences Corporation DHA Ester Emulsions
US20110223246A1 (en) * 2010-03-10 2011-09-15 Joar Opheim Docosahexaenoic acid bound in phospholipids and method of recovering same from a natural source
AU2011336856A1 (en) 2010-11-29 2013-07-04 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US20210176999A1 (en) 2011-04-17 2021-06-17 Omega Foods, LLC Prepared foods having high efficacy omega-6/omega-3 balanced polyunsaturated fatty acids
US8895074B2 (en) 2011-06-15 2014-11-25 Stable Solutions Llc Therapeutic application of parenteral krill oil
US10052352B2 (en) 2011-06-15 2018-08-21 Stable Solutions Llc Therapeutic application of parenteral krill oil
ES2643843T3 (es) * 2011-06-15 2017-11-24 Stable Solutions Llc Aplicación terapéutica de aceite de kril por vía parenteral
US8865685B2 (en) * 2011-06-30 2014-10-21 Johnson & Johnson Vision Care, Inc. Esters for treatment of ocular inflammatory conditions
US8846604B2 (en) 2011-09-02 2014-09-30 Artic Nutrition AS Lipid compositions with high DHA content
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013103958A1 (en) 2012-01-06 2013-07-11 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
WO2013142482A1 (en) 2012-03-20 2013-09-26 Particle Dynamics International, Llc Gelling agent-based dosage form
US20150110866A1 (en) * 2012-05-22 2015-04-23 Harold Gordon Cave Complexes and compositions containing curcumin
MX2020013922A (es) 2012-06-29 2022-08-15 Amarin Pharmaceuticals Ie Ltd Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina.
EP2890689B1 (en) 2012-08-29 2018-08-08 Université du Québec à Chicoutimi Dihydrochalcone derivatives and their use as antibiotic agents
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
CA2914213A1 (en) 2013-06-17 2014-12-24 Alain Moreau A method of increasing gipcr signalization in the cells of a scoliotic subject
WO2014201560A1 (en) 2013-06-17 2014-12-24 Chu Ste-Justine New markers for severe progression of idiopathic scoliosis and uses thereof to stratify scoliotic patients and predict the risk of developing scoliosis
WO2014201557A1 (en) 2013-06-17 2014-12-24 Chu Ste-Justine Gi protein phosphorylation as marker for scoliosis and scoliosis progression, methods of increasing gipcr signaling in scoliotic subjects
EP2826384A1 (de) 2013-07-16 2015-01-21 Evonik Industries AG Verfahren zur Trocknung von Biomasse
EP3024471B1 (en) 2013-07-22 2019-10-30 Université du Québec à Chicoutimi Use of plant extracts against herpes simplex virus
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US9610302B2 (en) 2013-12-05 2017-04-04 Buriva, LLC. Composition containing phospholipid-DHA and B vitamins
US9549937B2 (en) 2013-12-05 2017-01-24 Burvia, LLC. Composition containing phospholipid-DHA and folate
US9216199B2 (en) 2013-12-05 2015-12-22 Buriva, LLC Nutritional supplement containing phospholipid-DHA derived from eggs
US9233114B2 (en) 2013-12-05 2016-01-12 Buriva, LLC Dietary supplement containing phospholipid-DHA derived from eggs
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
BR112017006833B1 (pt) 2014-10-02 2022-09-13 Evonik Operations Gmbh Alimento para animais contendo ácido graxo poli-insaturado e processo para produzir o mesmo
WO2016050552A1 (de) 2014-10-02 2016-04-07 Evonik Degussa Gmbh Verfahren zur herstellung einer pufas enthaltenden biomasse mit hoher zellstabilität
BR112017005388B1 (pt) 2014-10-02 2022-09-13 Evonik Operations Gmbh Alimento para animais contendo biomassa de aurantiochytrium
ES2873094T3 (es) 2014-10-02 2021-11-03 Evonik Operations Gmbh Procedimiento para la producción de un pienso que contiene PUFAs mediante extrusión de una biomasa que contiene PUFAs de tipo Labyrinthulomycetes
KR102079747B1 (ko) 2015-02-11 2020-02-20 에이커 바이오마린 앤탁틱 에이에스 지질 조성물
PT3256003T (pt) 2015-02-11 2023-02-15 Aker Biomarine Antarctic As Processo de extração de lipídios
ES2866051T3 (es) * 2015-03-19 2021-10-19 Arctic Nutrition As Métodos para obtener fosfolípidos y composiciones de los mismos
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
CA3064774A1 (en) 2017-05-25 2018-11-29 The Governors Of The University Of Alberta Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase
SG10202108769WA (en) 2017-08-10 2021-09-29 Childrens Medical Ct Corp Methods and Compositions Relating to Emulsions Comprising Fish Oil and/or Omega-3 Fatty Acids
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA51766A (fr) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
CN109527123A (zh) * 2018-12-14 2019-03-29 大连大学 一种对慢性肠炎具有改善作用的调和油
KR20240012390A (ko) 2021-04-21 2024-01-29 애머린 파마슈티칼스 아일랜드 리미티드 심부전의 위험을 감소시키는 방법
WO2024057117A1 (en) 2022-09-14 2024-03-21 Societe Des Produits Nestle Sa Compositions and methods utilizing southern ocean mackerel oil for providing health benefits in an animal

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT333437B (de) * 1974-02-07 1976-11-25 Etapharm Chem Pharm Lab Ges M Verfahren zur herstellung von phosphatidkomplexen mit erhohtem phosphatidylathanolamingehalt aus tierischem material
DE3347269A1 (de) * 1983-12-28 1985-07-11 Pearson & Co (GmbH & Co), 5000 Köln Pharmazeutisch wirksame lecithine mit polyungesaettigten fettsaeuren
US4752618A (en) * 1984-07-12 1988-06-21 New England Deaconess Hospital Method of minimizing efects of infection through diet
US4678808A (en) * 1985-10-15 1987-07-07 Baxter Travenol Laboratories, Inc. Rapid acting intravenous emulsions of omega-3 fatty acid esters
DE3721137A1 (de) * 1987-06-26 1989-01-05 Dietl Hans Fettemulsion zur intravenoesen anwendung
IT1223290B (it) * 1987-07-27 1990-09-19 Indena Spa Acidi poliinsaturi ad azione vasocinetica e relative formulazioni farmaceutiche e cosmetiche
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production

Also Published As

Publication number Publication date
EP0660708B1 (en) 2002-04-17
WO1992021335A1 (en) 1992-12-10
JPH06508123A (ja) 1994-09-14
DE69232564T2 (de) 2002-09-26
SG64864A1 (en) 2001-01-16
US5434183A (en) 1995-07-18
SE9101642D0 (sv) 1991-05-30
JP3387498B2 (ja) 2003-03-17
CA2109611A1 (en) 1992-12-10
AU657969B2 (en) 1995-03-30
AU1910192A (en) 1993-01-08
PT100524B (pt) 1999-08-31
ATE216227T1 (de) 2002-05-15
ES2174833T3 (es) 2002-11-16
NZ242697A (en) 1994-02-25
DE69232564D1 (de) 2002-05-23
EP0660708A1 (en) 1995-07-05
IE921477A1 (en) 1992-12-02

Similar Documents

Publication Publication Date Title
PT100524A (pt) Emulsoes aquosas de oleos de origem vegetal e/ou marinha contendo fosfolipidos e composicoes que as contem
ES2173673T3 (es) Mezcla grasa y agentes dieteticos o farmaceuticos que las contienen.
Francois et al. Acute effects of dietary fatty acids on the fatty acids of human milk
Zock et al. Positional distribution of fatty acids in dietary triglycerides: effects on fasting blood lipoprotein concentrations in humans
KR940018091A (ko) 불포화 지방산을 포함하는 처방
KR880008797A (ko) 실리마린이 포함된 피부미용용 조성물
DE3881815D1 (de) Isotone omega-3-fettsaeurenhaltige fettemulsion und ihre verwendung.
TW360501B (en) Dietetically balanced milk product
KR940018090A (ko) 트리글리세라이드
AU608012B2 (en) Treatment or prevention of memory loss using essential fatty acid compositions
CA2189202A1 (en) Stable Edible Oil Composition
CA2147302A1 (en) A lipid composition for normalizing injury
AU609845B2 (en) Lipid emulsion intended for parenteral or enteral feeding
ES2118629T3 (es) Mezcla de grasas conteniendo fosfolipidos con acidos grasos lcp
NO952185D0 (no) Pai-skall
DE3470277D1 (en) Dietetic composition
Carlson The effect of nicotinic acid treatment on the chemical composition of plasma lipoprotein classes in man
OKITA et al. N-3 and n-6 fatty acid intake and serum phospholipid fatty acid composition in middle-aged women living in rural and urban areas in Okayama Prefecture
DE59002572D1 (de) Omega-3-fettsäurenhaltige fettemulsion zur endotrachealen applikation, ihre herstellung und anwendung.
US4999380A (en) Treatment of lipoprotein disorders associated with cholesterol metabolism
AU1489688A (en) Omega-3 fatty acids in traumatic injury treatment
NO950621L (no) Fiskefor
Sugano et al. Lipids and immunology
KAWASHIMA et al. Dietary manipulation by perilla oil and fish oil of hepatic lipids and its influence on peroxisomal β-oxidation and serum lipids in rat and mouse
DK0938339T3 (da) Formuleringer til topisk anvendelse indeholdende vitamin-E acetat

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19930331

FG3A Patent granted, date of granting

Effective date: 19990526

MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20001130